A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment (ANACOMP)
Latest Information Update: 30 Oct 2023
At a glance
- Drugs Anakinra (Primary) ; Immune globulin
- Indications Mucocutaneous lymph node syndrome
- Focus Therapeutic Use
- Acronyms ANACOMP
- 14 Apr 2023 Planned initiation date changed from 1 Mar 2023 to 1 May 2023.
- 10 Mar 2023 Planned End Date changed from 1 Feb 2027 to 1 Mar 2027.
- 10 Mar 2023 Planned primary completion date changed from 1 Feb 2027 to 1 Mar 2027.